Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Lead Financial Strategy During Critical Late-Stage Trials

Annovis Bio Inc. has appointed Mark Guerin as Chief Financial Officer to provide financial leadership as the company advances its lead drug candidate through critical late-stage clinical trials. The appointment comes at a pivotal time for the clinical-stage biopharmaceutical company, which is developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's disease. Guerin brings extensive financial management experience from previous roles in the biotechnology sector, most recently serving as CFO of Onconova Therapeutics, now Traws Pharma. During his tenure there, he oversaw multiple financings and a merger that formed the new entity. His background also includes senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand, providing him with a comprehensive understanding of the financial challenges and opportunities facing clinical-stage biotech companies.

The appointment is strategically timed as Annovis prepares for the late-stage development of buntanetap, the company's lead drug candidate. Guerin expressed enthusiasm about joining Annovis at this critical juncture, stating his eagerness to support the company's efforts to replicate buntanetap's early success in registrational studies. His financial expertise will be crucial in managing the complex funding requirements of late-stage clinical trials while positioning the company for potential commercialization. Annovis Bio maintains its corporate headquarters in Malvern, Pennsylvania, and focuses exclusively on developing innovative therapies for neurodegenerative conditions. The company's commitment to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's represents a significant area of unmet medical need. Additional information about the company's research and development programs can be found at https://www.annovisbio.com.

The appointment announcement was distributed through BioMedWire, a specialized communications platform focusing on biotechnology and biomedical sciences developments. BioMedWire operates as part of the Dynamic Brand Portfolio at IBN, providing comprehensive distribution services including wire solutions, media syndication, and social media distribution. More details about the platform's services are available at https://www.BioMedWire.com. This leadership change signals Annovis Bio's preparation for the next phase of clinical development, where robust financial management becomes increasingly critical. The company's focus on neurodegenerative diseases addresses a growing healthcare challenge as populations age worldwide, making the successful development of effective treatments both a medical priority and significant business opportunity.